Literature DB >> 22156755

Cerebrospinal fluid proteins predict longitudinal hippocampal degeneration in early-stage dementia of the Alzheimer type.

Lei Wang1, Anne M Fagan, Aarti R Shah, Mirza Faisal Beg, John G Csernansky, John C Morris, David M Holtzman.   

Abstract

OBJECTIVE: Biomarkers are needed to improve the sensitivity and accuracy of diagnosis, and also prognosis, in individuals with early Alzheimer disease (AD). Measures of brain structure and disease-related proteins in the cerebrospinal fluid (CSF) have been proposed as biomarkers, yet relatively little is known about the relationships between such measures. The present study was conducted to assess the relationship between CSF Aβ and tau protein levels and longitudinal measures of hippocampal structure in individuals with and without very mild dementia of the Alzheimer type.
DESIGN: A single CSF sample and longitudinal magnetic resonance scans were collected. The CSF samples were assayed for tau, phosphorylated tau181 (p-tau181), Aβ1-42, and Aβ1-40 using an enzyme-linked immunosorbent assay. Large-deformation diffeomorphic metric mapping was used to generate hippocampal surfaces, and a composite hippocampal surface (previously constructed from 86 healthy participants) was used as a structural reference. PATIENTS OR OTHER PARTICIPANTS: Thirteen participants with very mild AD (Clinical Dementia Rating, CDR 0.5) and 11 cognitively normal participants (CDR 0). INTERVENTION: None. MAIN OUTCOME MEASURES: Initial and rate-of-change measures of total hippocampal volume and displacement of the hippocampal surface within zones overlying the CA1, subiculum, and CA2-4+DG cellular subfields, and their correlations with initial CSF measures.
RESULTS: Lower CSF Αβ1-42 levels and higher tau/Αβ1-42 and p-tau181/Αβ1-42 ratios were strongly correlated with decreases in hippocampal volume and measures of progressive inward deformations of the CA1 subfield in participants with early AD, but not in cognitively normal participants.
CONCLUSIONS: Despite the small sample size, we found that Αβ1-42 related and tau-related CSF measures were associated with hippocampal degeneration in individuals with clinically diagnosed early AD and may reflect an association with a common underlying disease mechanism.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22156755      PMCID: PMC3309103          DOI: 10.1097/WAD.0b013e31823c0cf4

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  47 in total

1.  Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients.

Authors:  Lars-Olov Wahlund; Kaj Blennow
Journal:  Neurosci Lett       Date:  2003-03-20       Impact factor: 3.046

2.  Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals.

Authors:  Ira Driscoll; Yun Zhou; Yang An; Jitka Sojkova; Christos Davatzikos; Michael A Kraut; Weiguo Ye; Luigi Ferrucci; Chester A Mathis; William E Klunk; Dean F Wong; Susan M Resnick
Journal:  Neurobiol Aging       Date:  2010-02-21       Impact factor: 4.673

3.  The Clinical Dementia Rating (CDR): current version and scoring rules.

Authors:  J C Morris
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

4.  Mild cognitive impairment represents early-stage Alzheimer disease.

Authors:  J C Morris; M Storandt; J P Miller; D W McKeel; J L Price; E H Rubin; L Berg
Journal:  Arch Neurol       Date:  2001-03

5.  Rates of hippocampal atrophy correlate with change in clinical status in aging and AD.

Authors:  C R Jack; R C Petersen; Y Xu; P C O'Brien; G E Smith; R J Ivnik; B F Boeve; E G Tangalos; E Kokmen
Journal:  Neurology       Date:  2000-08-22       Impact factor: 9.910

6.  A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume.

Authors:  Randy L Buckner; Denise Head; Jamie Parker; Anthony F Fotenos; Daniel Marcus; John C Morris; Abraham Z Snyder
Journal:  Neuroimage       Date:  2004-10       Impact factor: 6.556

7.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

8.  Changes in hippocampal volume and shape across time distinguish dementia of the Alzheimer type from healthy aging.

Authors:  Lei Wang; Jeffrey S Swank; Irena E Glick; Mokhtar H Gado; Michael I Miller; John C Morris; John G Csernansky
Journal:  Neuroimage       Date:  2003-10       Impact factor: 6.556

9.  The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease.

Authors:  S E Arnold; B T Hyman; J Flory; A R Damasio; G W Van Hoesen
Journal:  Cereb Cortex       Date:  1991 Jan-Feb       Impact factor: 5.357

10.  In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life.

Authors:  John R Cirrito; Patrick C May; Mark A O'Dell; Jennie W Taylor; Maia Parsadanian; Jeffrey W Cramer; James E Audia; Jeffrey S Nissen; Kelly R Bales; Steven M Paul; Ronald B DeMattos; David M Holtzman
Journal:  J Neurosci       Date:  2003-10-01       Impact factor: 6.167

View more
  11 in total

1.  Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease.

Authors:  Daniela Bertens; Dirk L Knol; Philip Scheltens; Pieter Jelle Visser
Journal:  Alzheimers Dement       Date:  2014-08-20       Impact factor: 21.566

2.  Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease.

Authors:  Christine L Tardif; Gabriel A Devenyi; Robert S C Amaral; Sandra Pelleieux; Judes Poirier; Pedro Rosa-Neto; John Breitner; M Mallar Chakravarty
Journal:  Hum Brain Mapp       Date:  2017-11-21       Impact factor: 5.038

Review 3.  CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Authors:  Craig Ritchie; Nadja Smailagic; Anna H Noel-Storr; Obioha Ukoumunne; Emma C Ladds; Steven Martin
Journal:  Cochrane Database Syst Rev       Date:  2017-03-22

4.  Regional brain volumes relate to Alzheimer's disease cerebrospinal fluid biomarkers and neuropsychometry: A cross-sectional, observational study.

Authors:  Mark R Libowitz; Ke Wei; Thao Tran; Karen Chu; Kristina Moncrieffe; Michael G Harrington; Kevin King
Journal:  PLoS One       Date:  2021-07-22       Impact factor: 3.240

5.  Downstream effects of polypathology on neurodegeneration of medial temporal lobe subregions.

Authors:  L E M Wisse; S Ravikumar; R Ittyerah; S Lim; J Lane; M L Bedard; L Xie; S R Das; T Schuck; M Grossman; E B Lee; M D Tisdall; K Prabhakaran; J A Detre; G Mizsei; J Q Trojanowski; E Artacho-Pérula; M M de Iñiguez de Onzono Martin; M M Arroyo-Jiménez; M Muñoz Lopez; F J Molina Romero; M P Marcos Rabal; S Cebada Sánchez; J C Delgado González; C de la Rosa Prieto; M Córcoles Parada; D A Wolk; D J Irwin; R Insausti; P A Yushkevich
Journal:  Acta Neuropathol Commun       Date:  2021-07-21       Impact factor: 7.801

6.  Cerebrospinal fluid PKR level predicts cognitive decline in Alzheimer's disease.

Authors:  Julien Dumurgier; Francois Mouton-Liger; Pauline Lapalus; Magali Prevot; Jean-Louis Laplanche; Jacques Hugon; Claire Paquet
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

7.  Executive function changes before memory in preclinical Alzheimer's pathology: a prospective, cross-sectional, case control study.

Authors:  Michael G Harrington; Jiarong Chiang; Janice M Pogoda; Megan Gomez; Kris Thomas; Sarah Deboard Marion; Karen J Miller; Prabha Siddarth; Xinyao Yi; Feimeng Zhou; Sherri Lee; Xianghong Arakaki; Robert P Cowan; Thao Tran; Cherise Charleswell; Brian D Ross; Alfred N Fonteh
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

Review 8.  Why looking at the whole hippocampus is not enough-a critical role for anteroposterior axis, subfield and activation analyses to enhance predictive value of hippocampal changes for Alzheimer's disease diagnosis.

Authors:  Aleksandra Maruszak; Sandrine Thuret
Journal:  Front Cell Neurosci       Date:  2014-03-31       Impact factor: 5.505

9.  Hippocampal subfield atrophy in relation to cerebrospinal fluid biomarkers and cognition in early Parkinson's disease: a cross-sectional study.

Authors:  Ane Løvli Stav; Krisztina Kunszt Johansen; Eirik Auning; Lisa Flem Kalheim; Per Selnes; Atle Bjørnerud; Erik Hessen; Dag Aarsland; Tormod Fladby
Journal:  NPJ Parkinsons Dis       Date:  2016-01-14

10.  Grant Report on PREDICT-ADFTD: Multimodal Imaging Prediction of AD/FTD and Differential Diagnosis.

Authors:  Lei Wang; Ashley Heywood; Jane Stocks; Jinhyeong Bae; Da Ma; Karteek Popuri; Arthur W Toga; Kejal Kantarci; Laurent Younes; Ian R Mackenzie; Fengqing Zhang; Mirza Faisal Beg; Howard Rosen
Journal:  J Psychiatr Brain Sci       Date:  2019-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.